Clinical Trial Update: Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update describes an early-phase study of Lutathera in people with gastroenteropancreatic, bronchial, or unknown primary neuroendocrine tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Neuroendocrine Tumor
• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING